Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 8, 1999

View Archived Issues

New platinum analogue assessed in advanced gastric cancer patients

CCK-B antagonist CI-988 not effective in panic disorder

Calphostin C tested as photodynamic therapy in bladder cancer cell lines

Company Profile: Juvantia

Projected enrollment exceeded in Miravant's phase III AMD trials

Chiron and Scios complete FGF agreement

Select Therapeutics extends agreement with Institut Curie for cancer vaccine

DepoMed forms joint venture with Elan for gastric retention delivery technologies

Preparation and use of inhibitors of sodium-dependent Cl-/HCO3- exchange

CRCT discloses new cyclopropylindoles for ADEPT and/or GDEPT of cancer

Analgesic NOS inhibitors described in patent literature by Otsuka

New cephalosporins from Toyama active against resistant strains

Inhibitor of p38 MAP kinase significantly attenuates brain damage in stroke models

Japanese investigators describe work in the area of cysteine protease inhibitors at recent meeting

AstraZeneca drops TCAR MAb following phase II studies

Biogen reports phase II data for antipsoriatic agent and advances product to phase III

FDA advisory panel will review MS indication for Novantrone in early 2000

Hughes Institute team describes research into platinum complexes

Novartis reports setbacks and advances in the development of new chelating agents

Early indications of therapeutic benefit with Coagulin-B

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...